Edwards celebrates double-digit TAVR sales growth in Q4
Edwards Lifesciences reported $1.57 billion in sales for the fourth quarter of 2025, up 13.3% from the previous year, the company announced during a conference call with investors.
A significant majority of those sales—$1.16 billion, to be exact—came from the company’s thriving transcatheter aortic valve replacement (TAVR) division. That represented a year over year increase of 12%.
For the entire year, Edwards reported $4.5 billion in sales, up 8.6% from the previous year.
“Edwards’ strong fourth quarter and full year performance in 2025 reflect our differentiated strategy with a clear vision around three key elements: focusing solely on structural heart, solving large, urgent and very complex patient needs, and pursuing unique opportunities to innovate and lead, all achieved through excellent execution by our deeply experienced teams,” Bernard Zovighian, Edwards’ CEO, said in a statement. “Based on multiple catalysts and the company’s strong fourth quarter performance, we have increased confidence in our outlook for 2026 and believe that our 70 years of expertise in valve innovation and world-class evidence will create sustainable growth and expanded profitability.”
Impact of EARLY TAVR still being felt
During the conference call, Zovighian put a spotlight on the company’s considerable momentum in the TAVR space. Perhaps the company’s biggest success of the year was securing U.S. Food and Drug Administration (FDA) approval for its Sapien 3 TAVR platform for the treatment of asymptomatic severe aortic stenosis (AS).
Sapien 3 TAVR valves on display at TCT 2024.
That decision—which covered the Sapien 3, Sapien 3 Ultra and Sapien 3 Ultra Resilia TAVR valves—was primarily based on data from the Edwards-funded EARLY TAVR trial. It represented the first time any transcatheter heart valves were ever approved for treating asymptomatic severe AS. It also acted as a catalyst for the U.S. Centers for Medicare and Medicaid Services (CMS) to consider major policy updates that could, among other things, fully cover TAVR in asymptomatic patients.
“There is a renewed focus on Sapien across the healthcare ecosystem led by the seven-year PARTNER 3 and the 10-year PARTNER 2 data, which confirmed the long-term reliability and proven valve performance of the Sapien platform,” Zovighian said during the conference call. “This data, presented last October at TCT, reinforced the confidence physicians and patients have about TAVR and set a new clinical benchmark for safety, efficacy, durability and the lifetime management of patients. In addition, the practice-changing EARLY TAVR trial is resonating with the clinical community.”
With this progress in mind, Zovighian added, the company anticipates that its presence in the TAVR space will only expand as time goes on.
Continued progress for mitral and tricuspid valve treatments
Edwards also pointed to its progress in other areas. In total, sales for transcatheter mitral and tricuspid therapies totaled $156 million in the fourth quarter of 2025, up 40% from the previous year. The company also secured FDA approval for its Sapien M3 transcatheter mitral valve replacement system at the start of the year.
Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.